ERK/p38 MAP-kinases and PI3K are involved in the differential regulation of B7-H1 expression in DC subsets - PubMed (original) (raw)
ERK/p38 MAP-kinases and PI3K are involved in the differential regulation of B7-H1 expression in DC subsets
Svetlana Karakhanova et al. Eur J Immunol. 2010 Jan.
Free article
Abstract
Regulatory molecules of the B7-H-family expressed by DC are important for immune homeostasis, but their regulation is largely unknown. When investigating the pathways regulating B7-H1 expression in monocyte-derived DC (MoDC), freshly isolated myeloid DC (mDC) and plasmacytoid DC, respectively, we showed that in MoDC and mDC B7-H1 expression was upregulated by a standard cytokine cocktail, poly I:C or LPS. MoDC utilize ERK and PI3K pathways to upregulate B7-H1 in response to cytokines, whereas p38 kinase was predominantly utilized in response to poly I:C. In mDC, ERK and p38 pathways are involved in B7-H1 regulation, and similar to MoDC, mainly p38 signaling was required for poly I:C-induced expression of B7-H1. Plasmacytoid DC responded only to CpG with upregulation of B7-H1 and in addition to p38 also utilized the PI3K and ERK pathways to regulate B7-H1 expression. As a functional consequence of B7-H1 expression on DC, we demonstrate downmodulation of IFN-gamma production in T cells. Thus, the differential regulation of B7-H1 on DC subsets may suppress immune responses variably, depending on the target DC population. Further analysis of the regulatory mechanisms may facilitate the development of new immunosuppressive therapies, utilizing the regulation of B7-H1 expression on DC.
Similar articles
- 12-O-tetradecanoyl phorbol 13-acetate induces the expression of B7-DC, -H1, -H2, and -H3 in K562 cells.
Jang BC, Park YK, Choi IH, Kim SP, Hwang JB, Baek WK, Suh MH, Mun KC, Suh SI. Jang BC, et al. Int J Oncol. 2007 Dec;31(6):1439-47. Int J Oncol. 2007. PMID: 17982670 - Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H. Schreiner B, et al. J Neuroimmunol. 2004 Oct;155(1-2):172-82. doi: 10.1016/j.jneuroim.2004.06.013. J Neuroimmunol. 2004. PMID: 15342209 - Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement.
Nakahara T, Moroi Y, Uchi H, Furue M. Nakahara T, et al. J Dermatol Sci. 2006 Apr;42(1):1-11. doi: 10.1016/j.jdermsci.2005.11.004. Epub 2005 Dec 13. J Dermatol Sci. 2006. PMID: 16352421 Review. - IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells.
Lee SK, Seo SH, Kim BS, Kim CD, Lee JH, Kang JS, Maeng PJ, Lim JS. Lee SK, et al. J Dermatol Sci. 2005 Nov;40(2):95-103. doi: 10.1016/j.jdermsci.2005.06.008. Epub 2005 Aug 8. J Dermatol Sci. 2005. PMID: 16085391 - Signaling Pathways That Regulate Normal and Aberrant Red Blood Cell Development.
Wilkes MC, Shibuya A, Sakamoto KM. Wilkes MC, et al. Genes (Basel). 2021 Oct 19;12(10):1646. doi: 10.3390/genes12101646. Genes (Basel). 2021. PMID: 34681039 Free PMC article. Review.
Cited by
- Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.
Bazhin AV, von Ahn K, Fritz J, Bunge H, Maier C, Isayev O, Neff F, Siveke JT, Karakhanova S. Bazhin AV, et al. Oncoimmunology. 2022 Mar 1;11(1):2043037. doi: 10.1080/2162402X.2022.2043037. eCollection 2022. Oncoimmunology. 2022. PMID: 35251770 Free PMC article. - Regulation and Function of the PD-L1 Checkpoint.
Sun C, Mezzadra R, Schumacher TN. Sun C, et al. Immunity. 2018 Mar 20;48(3):434-452. doi: 10.1016/j.immuni.2018.03.014. Immunity. 2018. PMID: 29562194 Free PMC article. Review. - Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions.
Mi Y, Han J, Zhu J, Jin T. Mi Y, et al. Mol Neurobiol. 2021 Dec;58(12):6249-6271. doi: 10.1007/s12035-021-02495-7. Epub 2021 Sep 3. Mol Neurobiol. 2021. PMID: 34480337 Free PMC article. Review. - Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
Wang F, Wu L, Yin L, Shi H, Gu Y, Xing N. Wang F, et al. Clin Transl Med. 2022 Jun;12(6):e901. doi: 10.1002/ctm2.901. Clin Transl Med. 2022. PMID: 35696531 Free PMC article. - PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression.
Tung JN, Lin PL, Wang YC, Wu DW, Chen CY, Lee H. Tung JN, et al. Oncotarget. 2017 Dec 8;9(4):4637-4646. doi: 10.18632/oncotarget.23161. eCollection 2018 Jan 12. Oncotarget. 2017. PMID: 29435131 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous